SPORE in Soft Tissue Sarcoma

SPORE在软组织肉瘤中的长期目标是通过开发针对肉瘤类型和亚型特异性的分子、遗传、表观遗传和信号通路改变的疗法来降低软组织肉瘤的发病率和死亡率。为了实现这一目标，我们将把我们的努力集中在3个广泛的转化研究目标：1。明确肉瘤发生的共同和类型特异性分子机制，以确定新的合理治疗靶点。明确靶向治疗耐药的机制，3。在临床研究中开发和验证靶向治疗。为了实现这些目标，我们组建了一个综合的，多学科的基础和临床研究小组，所有研究人员都配备了独特的资源，前瞻性收集了超过27年的临床病理学和结果数据库，其中包含在MSKCC接受软组织肉瘤治疗的8300多名患者的数据。在过去的16年中，该数据库已与机构组织库相关联，在过去的7年中，该数据库已与用于建立原代肉瘤细胞系和人肉瘤小鼠异种移植模型的综合组织采购过程相关联。该孢子是围绕4个研究项目，3个核心，职业发展和发展研究计划。每个研究项目至少侧重于上述3个广泛的转化研究目标之一。RP-1（伊马替尼耐药）旨在确定新的治疗靶点，并为儿科和伊马替尼耐药GIST开发新的治疗策略。RP-2（PDGFR/PI 3 K/mT 0 R靶向）使用细胞系、异种移植模型和II期临床试验评估了在滑膜肉瘤和显示PDGFRA表达增加的肉瘤类型中靶向PDGFRA信号传导和减少活化Akt的策略。RP-3（靶标发现）旨在鉴定粘液纤维肉瘤和多形性恶性纤维组织细胞瘤中肿瘤发生的基因组驱动因素，以便鉴定新的治疗靶标。RP-4（表观遗传学疗法）旨在阐明滑膜肉瘤中SYT-SSX靶基因失调所涉及的表观遗传学机制和组蛋白密码子改变，以增强我们对滑膜肉瘤发病机制的理解，并指导新的选择性表观遗传学疗法的发展。

The long-term goal of the SPORE in Soft Tissue Sarcoma is to reduce morbidity and mortality from soft tissue sarcoma by developing therapies targeted to the molecular, genetic, epigenetic, and signaling pathway alterations that are specific to sarcoma type and subtype. To pursue this, we will focus our efforts on 3 broad translational research objectives: 1. Define shared and type-specific molecular mechanisms of sarcomagenesis to identify new rational therapeutic targets, 2. Define mechanisms of resistance to targeted therapies, 3. Develop and validate targeted therapies in clinical studies. To achieve these goals we have marshaled an integrated, multidisciplinary group of basic and clinical investigators all armed with a unique resource, a clinicopathologic and outcomes database prospectively collected over a 27-year period containing data for over 8300 patients treated for soft tissue sarcoma at MSKCC. This database has been linked for the past 16 years to an institutional tissue bank, and for the past 7 years to a comprehensive tissue procurement process for establishment of primary sarcoma cell lines and mouse xenograft models of human sarcoma. The SPORE is structured around 4 research projects, 3 cores, and career development and developmental research programs. Each research project focuses on at least one of the 3 broad translational research goals listed above. RP-1 (Imatinib Resistance) aims to identify new therapeutic targets and develop new treatment strategies for pediatric and imatinib-resistant GIST. RP-2 (PDGFR/PI3K/mT0R Targeting) evaluates strategies for targeting PDGFRA signaling and reducing activated Akt in synovial sarcoma and sarcoma types that show increased expression of PDGFRA using cell lines, xenograft models, and phase II clinical trials. RP-3 (Target Discovery) aims to identify genomic drivers of oncogenesis in myxofibrosarcoma and pleomorphic malignant fibrous histiocytoma so as to identify new therapeutic targets. RP-4 (Epigenetic Therapy) aims to elucidate the epigenetic mechanisms and histone code alterations involved in the deregulation of SYT-SSX target genes in synovial sarcoma so as to enhance our understanding of synovial sarcoma pathogenesis and guide the development of new selective epigenetic therapies.